Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

BACKGROUND: Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. This analysis reports benchmarks for clinical outcomes based on International Metastatic Ren...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Genitourin Cancer
Prif Awduron: Rini, Brian I, Hutson, Thomas E., Figlin, Robert A., Lechuga, Maria Josè, Valota, Olga, Serfass, Lucile, Rosbrook, Brad, Motzer, Robert J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690431/
https://ncbi.nlm.nih.gov/pubmed/29853320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.005
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg